Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 19/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 19/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 19/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 19/20 | 0.44 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.37 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.37 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.37 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5766316 | 1.00 | PDK1 (0.44) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL5764585 | 1.00 | PDK1 (0.44) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL13141672 | 0.87 | CCNE2 (0.31) | — | |
| SCHEMBL7833134 | 0.84 | PDK1 (0.45) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL7829272 | 0.84 | PDK1 (0.46) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL7835701 | 0.83 | PDK1 (0.48) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL5766893 | 0.82 | CCNE2 (0.43) | — | |
| SCHEMBL3621875 | 0.82 | METAP1 (0.41) | — | |
| SCHEMBL7834669 | 0.81 | PDK1 (0.43) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL7820592 | 0.81 | PDK1 (0.43) | PDK1PDK2PDK3PDK4ABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267796-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-0979821-B1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KK (JP) | 2006-09-13 | — | — | EP | disclosed |
| EP-0798288-B1 | TRICICLIC COMPOUNDS | KYOWA HAKKO KOGYO KK (JP) | 2001-05-16 | — | — | EP | disclosed |
| US-6211227-B1 | SULFUR CONTAINING TRICYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-04-03 | — | — | US | disclosed |
| EP-0979821-A1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-02-16 | — | — | EP | disclosed |
| EP-0798288-A1 | TRICICLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267796-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | SLC10A2, ADORA3, HRH2 | PDK1 4523/4885PDK2 4239/4885PDK3 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.